Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Scilex Bio, a Controlling Interest of Joint Venture
KDS2010 (Tisolagiline), a reversible selective monoamine oxidase B (MAO-B) inhibitor, is being studied for treating Alzheimer's disease by influencing astrocytic GABA inhibition. It attenuates astrocytic GABA levels, enhances synaptic transmission, and improves learning and memory in mouse models. A Phase 2 clinical trial is currently recruiting in South Korea, with a U.S. cohort to be added in 2025. The Alzheimer’s drug market is projected to exceed $15 billion by 2030.
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type
New TNBC treatment at Roswell Park achieves 66% complete remission without immune-related adverse events, using a combination of chemotherapy and immunotherapy.
Scilex Holding Company Announces Presentation of Data at the 2024 American College of ...
Scilex Holding Company announced data presentation on GLOPERBA® (colchicine oral solution) at the 2024 American College of Rheumatology Convergence, highlighting its precision dosing for gout patients, including reduced daily dose for severe renal impairment.
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company ...
Scilex Holding Company announces successful Phase II meeting with FDA, paving the way for NDA submission upon Phase III trials completion for SP-103, a next-generation lidocaine topical system for chronic neck pain. Market research projects SP-103's peak sales potential at $1.2 billion annually by the 6th year post-launch.
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of
Scilex Holding Company announces successful Phase II meeting with FDA, paving the way for NDA submission for SP-103, a triple-strength lidocaine topical system for chronic neck pain. Market research projects SP-103 could achieve $1.2 billion in annual sales by the 6th year post-launch.
Scilex Holding Company Announces that its Board of
Scilex Holding Company explores spinoff or public listing of Scilex Pharmaceuticals in markets including Hong Kong to unlock potential value. Scilex Pharma has three FDA-approved products: ZTlido® for neuropathic pain, ELYXYB® for migraine, and Gloperba® for gout. A next-generation product, SP-103, targets acute pain with projected peak sales of $1.2 billion.
Scilex Holding Company Announces that its Board of Directors has Authorized Management ...
Scilex Holding Company explores spinoff or public listing of Scilex Pharmaceuticals in markets including Hong Kong to unlock potential value. Scilex Pharma has three FDA-approved products: ZTlido®, ELYXYB®, and Gloperba®, with SP-103, a next-generation lidocaine topical system, targeting $1.2 billion in peak sales.
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies in the Spotlight
Tonix Pharmaceuticals aims to lead in non-addictive pain management with TNX-102 SL, a non-opioid drug targeting fibromyalgia. The FDA's Fast Track designation highlights the need for new treatments. Tonix is nearing NDA submission for TNX-102 SL, which could offer a new pharmacotherapy for fibromyalgia after 15 years. The push for non-addictive painkillers is driven by the opioid crisis and government initiatives like the HEAL Initiative. Vertex's VX-458, also under Priority Review, addresses acute pain. Both drugs represent crucial steps in reducing opioid reliance.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath